August 18, 2016 08:39 AM EDTUpdated September 18, 11:33 PM
Bioregnum
Opinion

BioReg­num: The fog of M&A. What con­sti­tutes a le­git buy­out ‘scoop’ these days?

 

Bioreg­num
The view from End­points

The com­pe­ti­tion be­tween Reuters, Bloomberg and the Wall Street Jour­nal to break the next big M&A sto­ry …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times